SHANGHAI, Oct. 30 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appointment of Dr. Tom Gu as Vice President, effective November 2. In this role, Dr. Gu will oversee the development of China Biotics' probiotics products in order to meet the growing demand the Company has seen from China and the global market.
Dr. Gu has an impressive background in biochemistry and pathology with
extensive practical experience in U.S. FDA-certified medical applications
obtained from his work at China-based medical companies over the past eight
years. Previously, Dr. Gu served as project manager for Life Technologies
Corporation in the United States. Dr. Gu graduated from the
"We are very excited to have someone of Dr. Gu's caliber join us and lead our research and development team," said Mr. Jinan Song, Chairman and Chief Executive Officer of China Biotics. "His impressive academic achievements and practical experience will enhance and solidify our R&D capabilities, which will be of critical importance as we expand the scale of our operations. We are currently in trial production at our new 150 metric ton probiotics facility, which we expect to complete by year end. At that point, we will begin the second phase of our capacity expansion. Dr. Gu's education and practical experience in United States will be an asset in evaluating and assessing potential overseas business opportunities."
"I'm delighted to have the opportunity to join a company with such a strong reputation for innovation and quality as China-Biotics. I look forward to sharing my knowledge and experience in order to help China-Biotics further extend its reach and reputation as a leading probiotics company," said Dr. Gu.
About China-Biotics, Inc.
China-Biotics, Inc., a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact: Eva Yan, CFO Email: email@example.com Web: http://www.chn-biotics.com CCG Investor Relations Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE China-Biotics, Inc.
|SOURCE China-Biotics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved